Accurate glycosylation of proteins is essential for their function and their intracellular transport. Numerous diseases have been described, where either glycosylation or intracellular transport of proteins is impaired. Coat protein I (COPI) is involved in anterograde and retrograde transport of proteins between endoplasmic reticulum and Golgi, where glycosylation takes place, but no association of defective COPI proteins and glycosylation defects has been described so far. We identified a patient whose phenotype at a first glance was reminiscent of PGM1 deficiency, a disease that also affects N-glycosylation of proteins. More detailed analyses revealed a different disease with a glycosylation deficiency that was only detectable during episodes of acute illness of the patient. Trio-exome analysis revealed a de novo loss-of-function mutation in ARCN1, coding for the delta-COP subunit of COPI. We hypothesize that the capacity of flow through Golgi is reduced by this defect and at high protein synthesis rates, this bottleneck also manifests as transient glycosylation deficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.a.61190DOI Listing

Publication Analysis

Top Keywords

novo loss-of-function
8
loss-of-function mutation
8
coat protein
8
intracellular transport
8
transport proteins
8
glycosylation deficiency
8
glycosylation
6
proteins
5
transient n-glycosylation
4
n-glycosylation abnormalities
4

Similar Publications

Signal transducer and activator of transcription 1 (STAT1) gene mutations have broad clinical phenotypes, classified by the inheritance pattern and functional state. Individuals with autosomal dominant STAT1 deficiency are more susceptible to intracellular bacteria, the hallmark of which is Mendelian susceptibility to mycobacterial diseases (MSMDs) that are associated with increased risks of invasive disease by weakly virulent mycobacteria. We report a novel heterozygous missense mutation in exon 23 of the STAT1 gene (NM_007315.

View Article and Find Full Text PDF

Multi-modal investigation reveals pathogenic features of diverse DDX3X missense mutations.

PLoS Genet

January 2025

Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.

De novo mutations in the RNA binding protein DDX3X cause neurodevelopmental disorders including DDX3X syndrome and autism spectrum disorder. Amongst ~200 mutations identified to date, half are missense. While DDX3X loss of function is known to impair neural cell fate, how the landscape of missense mutations impacts neurodevelopment is almost entirely unknown.

View Article and Find Full Text PDF

CTNNB1 syndrome mouse models.

Mamm Genome

January 2025

The Gene Therapy Research Institute, CTNNB1 Foundation, Ljubljana, 1000, Slovenia.

CTNNB1 syndrome is a rare neurodevelopmental disorder, affecting children worldwide with a prevalence of 2.6-3.2 per 100,000 births and often misdiagnosed as cerebral palsy.

View Article and Find Full Text PDF

Genetic features and pharmacological rescue of novel Kv7.2 variants in patients with epilepsy.

J Med Genet

January 2025

Heilongjiang Provincial Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, Heilongjiang, China

Background: Increasing evidence indicates a robust correlation between epilepsy and variants of the Kv7.2 () channel, which is critically involved in directing M-currents and regulating neuronal excitability within the nervous system. With the advancement of next-generation sequencing, the identification of variants has surged.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!